健民集团(600976) - 2024 Q3 - 季度财报

Financial Performance - The company's operating revenue for Q3 2024 was ¥871,720,993, a decrease of 8.83% compared to the same period last year[2]. - The net profit attributable to shareholders for Q3 2024 was ¥82,258,112, down 49.46% year-on-year[2]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥76,514,611, a decrease of 36.37% compared to the same period last year[4]. - The basic earnings per share for Q3 2024 was ¥0.54, reflecting a decline of 49.53% year-on-year[4]. - The weighted average return on equity for Q3 2024 was 3.50%, down 3.89 percentage points from the previous year[4]. - Total operating revenue for the first three quarters of 2024 was CNY 2,881,317,090.47, a decrease of 7.57% compared to CNY 3,117,619,192.23 in the same period of 2023[17]. - Net profit for the third quarter of 2024 was CNY 324,587,553.14, a decline of 22.08% from CNY 416,690,389.61 in the same quarter of 2023[19]. - Earnings per share for the third quarter of 2024 were CNY 2.10, compared to CNY 2.72 in the same period of 2023, indicating a decrease in profitability per share[21]. Assets and Liabilities - Total assets at the end of Q3 2024 amounted to ¥4,205,324,282, an increase of 0.90% from the end of the previous year[4]. - The equity attributable to shareholders at the end of Q3 2024 was ¥2,393,859,370, up 6.50% from the end of the previous year[4]. - The company's total liabilities as of the end of the third quarter of 2024 were CNY 1,799,048,552.39, a slight decrease from CNY 1,911,466,639.41 in the previous year[19]. - Total current liabilities decreased to RMB 1,718,469,147.38 from RMB 1,856,942,135.52, a reduction of about 7.4%[15]. Cash Flow - The net cash flow from operating activities for the year-to-date was ¥105,781,248, a decrease of 36.99% year-on-year[4]. - In the first three quarters of 2024, the cash inflow from operating activities was CNY 3,240,143,517.02, a slight increase from CNY 3,191,838,251.25 in the same period of 2023, representing a growth of approximately 1.5%[22]. - The net cash flow from operating activities for the first three quarters of 2024 was CNY 105,781,248.03, down from CNY 167,889,871.63 in 2023, indicating a decline of about 37.0%[22]. - Cash inflow from financing activities totaled CNY 194,147,900.71 in the first three quarters of 2024, up from CNY 155,402,505.49 in 2023, marking an increase of about 24.9%[23]. - The net cash flow from financing activities was CNY -97,605,918.79 in 2024, worsening from CNY -48,111,642.62 in 2023, indicating a decline of approximately 102.1%[23]. Operational Efficiency - The company experienced a decline in pharmaceutical sales due to changes in marketing strategies and increased procurement costs[9]. - Total operating costs for the third quarter of 2024 were CNY 2,770,674,778.90, down from CNY 2,880,978,852.52 in the previous year, reflecting a cost reduction strategy[19]. - The company reported a decrease in sales expenses to CNY 918,789,285.72 from CNY 1,019,762,565.19, indicating improved cost management in sales operations[19]. Investments and Research - Research and development expenses for the first three quarters of 2024 were CNY 60,448,309.19, an increase from CNY 52,007,975.33 in the same period of 2023, reflecting a commitment to innovation[19]. - The company reported a significant increase in long-term equity investments to RMB 475,702,517.81 from RMB 410,014,958.81, a rise of about 16.0%[14]. Other Financial Metrics - The company reported non-recurring gains of ¥5,743,501 for the current period, with a total of ¥50,803,367 for the year-to-date[5]. - Deferred income increased significantly to CNY 46,989,387.01 from CNY 18,610,226.96, suggesting potential future revenue recognition[19]. - The ending balance of cash and cash equivalents as of the end of the third quarter of 2024 was CNY 180,774,348.01, compared to CNY 110,315,766.78 at the end of the same period in 2023, showing an increase of about 63.7%[23]. - The company has not disclosed any new product developments or market expansion strategies in this report[12].